Customers can now use the end-to-end solution to translate
research to the clinic to improve disease outcomes in the
future.
NEW
YORK, July 31, 2024 /PRNewswire/ -- Allelica,
Inc., a leading provider of software tools for polygenic risk
scores (PRS), announced a collaboration with Thermo Fisher
Scientific, the world leader in serving science, to utilize
Allelica's bioinformatics software with Thermo Fisher's Axiom™ Human Genotyping
Microarrays to provide end-to-end solutions for genomics research
customers.
The genetic research and medical communities are gaining
interest in PRS for disease risk prediction of common diseases and
clinical trial patient stratification. PRS quantifies the total
risk of specific diseases based on common variants in a patient's
genome and is then used to categorize groups of subjects or
research participants based on their risk levels. This information
can help make well-informed decisions and improve outcomes.
Allelica offers a wide selection of PRS validated in multiple
ancestries, allowing implementation in diverse populations.
While PRS has traditionally required extensive bioinformatics
resources and investment, through Allelica's collaboration with
Thermo Fisher, clinical researchers
now have access to off-the-shelf workflows including everything
needed to create and implement PRS, from sample prep and
microarrays to risk interpretation reports.
"Providing PRS tools to deliver disease risk profiles will
enable significant advances in precision medicine, including
development of personalized treatment strategies for patients,"
said Giordano Bottà, chief executive officer and co-founder of
Allelica. "By collaborating with Thermo
Fisher, a leader in predictive genomics, to streamline data
analysis, we can also help researchers spend more time on research
which will ultimately improve disease outcomes in the future."
Allelica's software for new PRS development, available on the
cloud or on-premises, runs a series of PRS algorithms
simultaneously to identify the most predictive model in diverse
populations. It also allows researchers to validate a PRS on an
independent, ancestry-diverse dataset to help understand clinical
applicability.
"Microarrays are a trusted and cost-effective solution for
genomic research, and Thermo Fisher
is continuously innovating to deliver improved workflow solutions
as reflected in our recent launch of the Axiom™ PangenomiX Array to
provide the most comprehensive population coverage on a
high-throughput array to date," said Kevin
Lowitz, vice president and general manager, microarray,
Thermo Fisher. "By integrating
Allelica's software with our microarray platform, we can help solve
a pain point for researchers so they can focus on translating
genetic insights into impactful actions."
All Applied Biosystems™ Axiom™ Human Genotyping Arrays are
for Research Use Only. Not for use in diagnostic purposes.
About Allelica
Allelica is a leading genomic software
company that specializes in secure and scalable solutions to
implement bioinformatics solutions. Allelica's technology combines
world-class datasets with the most advanced algorithms to build
polygenic risk scores (PRS) with the highest predictive power for
estimating disease risk. Allelica's tools translate the enormous
potential of genomic data into practical tools that can be used to
identify individuals with a high genetic susceptibility for
life-threatening diseases. Through the incorporation of genetics
into disease risk assessments, Allelica is helping to build the
foundations of preventive medicine by helping to identify those for
whom early intervention and behavior modification could help reduce
lifetime risk. To learn more, visit allelica.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/axiom-human-genotyping-arrays-now-integrated-with-allelica-polygenic-risk-score-software-and-reports-302210074.html
SOURCE Allelica, Inc.